Deutsche Bank Ag\ I Mab Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$8.27 - $18.43 $1.38 Million - $3.08 Million	-166,920 Reduced 98.58%	2,400 $27,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $135,143 - $505,764	10,777 Added 6.8%	169,320 $2.75 Million
Q4 2021 Feb 11, 2022	SELL	$45.28 - $74.5 $51,709 - $85,079	-1,142 Reduced 0.72%	158,543 $7.51 Million
Q3 2021 Nov 04, 2021	BUY	$57.18 - $84.43 $741,281 - $1.09 Million	12,964 Added 8.84%	159,685 $11.6 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $7.02 Million - $12.3 Million	146,721 New	146,721 $12.3 Million
Q1 2021 May 13, 2021	SELL	$44.38 - $63.97 $8,876 - $12,794	-200 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $3,228 - $4,620	98 Added 96.08%	200 $9,000
Q3 2020 Nov 12, 2020	BUY	$27.46 - $47.03 $2,800 - $4,797	102 New	102 $5,000

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.